Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 16 Aug 2023
First-line atezolizumab monotherapy is linked to improved overall survival compared to single-agent chemotherapy in patients with non-small cell lung cancer (NSCLC) who are ineligible for platinum-based chemotherapy.
Read Full NewsA novel oral ketamine drug shows a signal for reducing depressive symptoms with minimal dissociative effects.
Men who receive personalized estimates of the likelihood of raised prostate-specific antigen levels are more likely to decide to get screening than those who receive general information on pros and cons.
Upadacitinib and infliximab offer rapid relief from symptoms in biologic-naive patients with moderate-to-severe ulcerative colitis.
Clinicians and patients are already relying on AI, while hospitals are still building the oversight to keep up.
A culturally tailored lifestyle program improves cognition significantly more than standard health advice among older adults at risk for dementia across Latin America.
People with intellectual disabilities who have physical health problems or sensory impairments face a higher risk for challenging behaviours.
Rimegepant is safe and effective in patients with migraine not responding to multiple prior preventive therapies, a real-world study shows.
1.
Nearly 6 Million Deaths From Five Major Cancer Types Averted Since 1975
2.
Number of cancer survivors in the US reaches 18.6 million—projected to exceed 22 million by 2035
3.
Powerlifting through breast cancer: How a breast cancer survivor defied chemotherapy with strength training
4.
How Do Younger People Fare With Stool Tests for CRC Screening?
5.
Colon cancer and exercise: Can physical activity reprogram genes?
1.
The Importance of Maintaining Normal Calcium Levels in Your Body
2.
Precision Medicine and Genomics: Revolutionizing Healthcare Through Personalized Treatment
3.
Radioligand Therapy Advances: PSMA, Neuroendocrine, and Solid Tumor Clinical Insights
4.
Mast Cell-Tumor Cell Interactions in OSCC: Genetic and microRNA Insights
5.
Safety Monitoring of Complement Inhibitors in Hematologic Disorders
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
4.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
5.
Efficient Management of First line ALK-rearranged NSCLC - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge